Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (DE:KUR)
FRANKFURT:KUR
KUR Stock Chart & Stats
€8.36
-€0.16(-1.94%)
At close: 4:00 PM EST
€8.36
-€0.16(-1.94%)
Day’s Range― - ―
52-Week Range€4.68 - €17.27
Previous CloseN/A
Volume0.00
Average Volume (3M)182.00
Market Cap
$753.19M
Enterprise Value€245.46M
Total Cash (Recent Filing)$549.66M
Total Debt (Recent Filing)$14.13M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Mar 03, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding87,017,520
10 Day Avg. Volume460
30 Day Avg. Volume182
Financial Highlights & Ratios
PEG Ratio1.50
Price to Book (P/B)1.81
Price to Sales (P/S)13.93
P/FCF Ratio5.61
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue2.36
Enterprise Value/Gross Profit2.95
Enterprise Value/Ebitda-1.08
Forecast
1Y Price Target
$22.75Price Target Upside172.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial StabilityCash reserves, along with expected funding, are believed to support operations through 2027 and ziftomenib development through the KOMET-017 topline.
Market PotentialZiftomenib addresses a difficult-to-treat AML subpopulation, offering multiple novel treatment options for patients with NPM1 mutations, which account for approximately 30% of AML cases.
Product LaunchKura is preparing for the potential launch of its first commercial product, ziftomenib, with a PDUFA date, supported by data showing a 23% CR/CRh rate and 33% ORR.
Bears Say
CompetitionSNDX announced approval of Revuforj in relapsed/refractory AML with NPM1 mutation, which includes an updated Black Box warning for Torsades de Pointe ventricular tachycardia.
Drug ResistanceDespite important clinical progress with small-molecule targeted therapies, resistance limits the potential of these drugs, and their efficacy as monotherapy may be restricted.
Investor SentimentShort interest is significant at 16.7% of the float, indicating that a portion of investors may have a negative outlook on the stock.
Kura Oncology News
KUR FAQ
What was Kura Oncology’s price range in the past 12 months?
Kura Oncology lowest stock price was €4.68 and its highest was €17.27 in the past 12 months.
What is Kura Oncology’s market cap?
Kura Oncology’s market cap is $753.19M.
When is Kura Oncology’s upcoming earnings report date?
Kura Oncology’s upcoming earnings report date is Mar 03, 2026 which is in 116 days.
How were Kura Oncology’s earnings last quarter?
Kura Oncology released its earnings results on Nov 04, 2025. The company reported -€0.74 earnings per share for the quarter, missing the consensus estimate of -€0.635 by -€0.104.
Is Kura Oncology overvalued?
According to Wall Street analysts Kura Oncology’s price is currently Undervalued.
Does Kura Oncology pay dividends?
Kura Oncology does not currently pay dividends.
What is Kura Oncology’s EPS estimate?
Kura Oncology’s EPS estimate is -0.19.
How many shares outstanding does Kura Oncology have?
Kura Oncology has 87,017,520 shares outstanding.
What happened to Kura Oncology’s price movement after its last earnings report?
Kura Oncology reported an EPS of -€0.74 in its last earnings report, missing expectations of -€0.635. Following the earnings report the stock price went down -4.477%.
Which hedge fund is a major shareholder of Kura Oncology?
Currently, no hedge funds are holding shares in DE:KUR
Kura Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.75 (172.10% Upside)
$22.75 (172.10% Upside)
Blogger Sentiment
Bullish
DE:KUR Sentiment 66%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $198.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-43.26%
12-Months-Change
Fundamentals
Return on Equity
-65.10%
Trailing 12-Months
Asset Growth
35.62%
Trailing 12-Months
Company Description
Kura Oncology
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.
KUR Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong focus on advancing clinical development, particularly for ziftomenib, with significant progress in trials and preparations for a potential FDA approval. Despite financial challenges, the company's strategic partnerships and clinical advancements position it well for future growth. The sentiment is positive, driven by strong clinical and commercial progress.View all DE:KUR earnings summariesKUR Stock 12 Month Forecast
Average Price Target
€22.75
▲(172.10% Upside)
Technical Analysis
Oruka Therapeutics
―
Phathom Pharmaceuticals
―
Keros Therapeutics
―
Tyra Bioscience
―
Septerna, Inc.
―
Options Prices
Currently, No data available
---